Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.76 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.76 |
| ▸ | IKZF3 | Q9UKT9 | 6/20 | 0.58 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133984 | 1.00 | CRBN (0.76) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL23124803 | 1.00 | CRBN (0.76) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL20294798 | 0.99 | CRBN (0.75) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL20294800 | 0.99 | CRBN (0.75) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL20294765 | 0.95 | CRBN (0.75) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL20294768 | 0.95 | CRBN (0.75) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL23302478 | 0.94 | CRBN (0.76) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL24459261 | 0.90 | CRBN (0.68) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL30862211 | 0.90 | CRBN (0.68) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL29922394 | 0.90 | CRBN (0.77) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019371-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-01-16 | — | — | US | disclosed |
| WO-2023077057-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023077057-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11236090-B2 | Substituted glutarimides as CDK inhibitors | SHANGHAI MEIZER PHARMACEUTICALS CO., LTD. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20210363148-A1 | COMPOUND HAVING BRUTON'S TYROSINE KINASE (BTK)-INHIBITION AND DEGRADATION ACTIVITY | SHANGHAI MEIZER PHARMACEUTICALS CO LTD (CN) | 2021-11-25 | — | — | US | disclosed |
| US-11155561-B2 | Substituted glutarimides as Btk inhibitors | SHANGHAI MEIZER PHARMACEUTICALS CO., LTD. (CN) | 2021-10-26 | — | — | US | disclosed |
| WO-2021055936-A1 | SMALL-MOLECULE INHIBITORS FOR THE Β-CATENIN/B-CELL LYMPHOMA 9 PROTEIN−PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055936-A1 | SMALL-MOLECULE INHIBITORS FOR THE Β-CATENIN/B-CELL LYMPHOMA 9 PROTEIN−PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20200216450-A1 | COMPOUND FOR INHIBITING AND DEGRADING CDK | SHANGHAI MEIZER PHARMACEUTICALS CO., LTD. (CN) | 2020-07-09 | — | — | US | disclosed |
| EP-3677584-A1 | COMPOUND HAVING BRUTON'S TYROSINE KINASE (BTK)-INHIBITION AND DEGRADATION ACTIVITY | Shanghai Meizer Pharmaceuticals Co., Ltd. (CN) | 2020-07-08 | — | — | EP | disclosed |
| US-20200199132-A1 | COMPOUND HAVING BRUTON'S TYROSINE KINASE (BTK)-INHIBITION AND DEGRADATION ACTIVITY | SHANGHAI MEIZER PHARMACEUTICALS CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| US-20200199106-A1 | COMPOUND FOR INHIBITING AND DEGRADING TYROSINE PROTEIN KINASE ALK | SHANGHAI MEIZER PHARMACEUTICALS CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363148-A1 | COMPOUND HAVING BRUTON'S TYROSINE KINASE (BTK)-INHIBITION AND DEGRADATION ACTIVITY | BTK, LYN, SYK | CRBN 413/4885DDB1 1265/4885IKZF3 1314/4885 |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | CRBN 444/4885DDB1 471/4885IKZF3 932/4885 |
| US-20200199106-A1 | COMPOUND FOR INHIBITING AND DEGRADING TYROSINE PROTEIN KINASE ALK | ALK, BCR, BCL6 | CRBN 183/4885DDB1 1835/4885IKZF3 966/4885 |
| US-11155561-B2 | Substituted glutarimides as Btk inhibitors | BTK, SYK, GCDH | CRBN 686/4885DDB1 940/4885IKZF3 1203/4885 |
| US-20200216450-A1 | COMPOUND FOR INHIBITING AND DEGRADING CDK | CDK1, CDK6, CDK9 | CRBN 790/4885DDB1 605/4885IKZF3 1512/4885 |
| US-11236090-B2 | Substituted glutarimides as CDK inhibitors | CDKL1, CDKL2, CDK2 | CRBN 1350/4885DDB1 219/4885IKZF3 3383/4885 |
| US-20200199132-A1 | COMPOUND HAVING BRUTON'S TYROSINE KINASE (BTK)-INHIBITION AND DEGRADATION ACTIVITY | BTK, SYK, LYN | CRBN 408/4885DDB1 1190/4885IKZF3 819/4885 |
| US-20250019371-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | CRBN 108/4885DDB1 138/4885IKZF3 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.